Hyperbaric
Research Library

Key Finding: RCT of 80 patients showed HBOT group had 62% ulcer area reduction vs 41% in controls (p<0.001). Complete healing at 90 days: 62.5% vs 30%.

Key Finding: Comprehensive review confirming HBOT supports fibroblast activity, collagen cross-linking, angiogenesis, and antimicrobial defenses in post-surgical wound healing.

Key Finding: Reviews HBOT as an effective adjunct for chronic wound healing, supporting oxygen delivery to hypoxic wound beds and promoting tissue repair.

Key Finding: Study of 53 patients showed HBOT improved both wound healing and cognitive function scores (MMSE, verbal fluency) in chronic wound patients.

Key Finding: Reviews established clinical evidence for HBOT in non-healing wounds and ischemia, with emerging evidence for metabolic disorder management.

Key Finding: HBOT combined with skin grafting achieved complete coverage of a treatment-resistant chronic sickle cell leg ulcer, demonstrating synergy between HBOT and grafting.

Key Finding: Multicenter study confirmed HBOT is safe and well-tolerated in elderly patients (≥75 years), with adverse events comparable to younger populations.

Key Finding: Narrative review supports HBOT as an adjunct for wound healing in high-risk dental indications including osteoradionecrosis and medication-related osteonecrosis.

Key Finding: Economic analysis demonstrates oxygen-based wound therapies provide cost-effective healing outcomes compared to standard negative-pressure wound therapy.

Key Finding: Case series demonstrates HBOT improves wound healing in calciphylaxis, a rare and life-threatening complication of chronic kidney disease with high mortality.

Key Finding: Third Cochrane update: HBOT significantly improves healing outcomes in late radiation tissue injury across multiple tissue types with acceptable safety profile.

Key Finding: International guideline by ISOO-MASCC-ASCO provides evidence-based recommendations supporting HBOT for prevention and management of jaw osteoradionecrosis.

Key Finding: Reviews recent advances in treating mandibular osteoradionecrosis, supporting HBOT as part of a multimodal treatment approach for this morbid complication.

Key Finding: Meta-analysis of RCTs and cohort studies demonstrates HBOT significantly improves treatment outcomes for jaw osteoradionecrosis.

Key Finding: About 5% of radiotherapy patients develop severe late toxicity. HBOT has been used for decades with multiple publications showing benefit for radiation injuries.

Key Finding: 15-year experience treating maxillary bone osteoradionecrosis with HBOT demonstrates consistent clinical benefit and high patient satisfaction.

Key Finding: Cochrane review finds HBOT improves outcomes in radiation cystitis, proctitis, and osteoradionecrosis with evidence of new blood vessel formation in irradiated tissue.

Key Finding: Osteonecrosis from radiation, medication, or infection benefits from multimodal treatment including HBOT, which promotes angiogenesis in damaged bone.

Key Finding: HBOT shows consistent benefit in treating delayed radiation injury and success in preventing radiation injury, supporting its clinical use.

Key Finding: Cochrane review of 14 RCTs: HBOT improves radiation proctitis healing (NNT=5), radiation cystitis, and mandibular osteoradionecrosis outcomes.

Key Finding: Meta-analysis of RCTs: HBOT as adjunct to steroids significantly improves hearing recovery in SSNHL, with greater benefit when started within 14 days.

Key Finding: Comprehensive review confirms HBOT as an effective non-pharmacological treatment gaining increasing attention for SSNHL management.

Key Finding: Systematic review and meta-analysis evaluating HBOT for SSNHL demonstrates significant hearing improvements, supporting its use as adjunctive therapy.

Key Finding: Umbrella review of all existing evidence confirms HBOT efficacy in SSNHL treatment, synthesizing findings from multiple systematic reviews.

Key Finding: HBOT within 3 days of symptom onset showed hearing improvement even without conventional corticosteroid treatment, highlighting the importance of early HBOT.

Key Finding: Clinical review supports HBOT as a valuable adjunctive treatment for SSNHL, particularly for patients not responding to initial steroid therapy.

Key Finding: AAO-HNS clinical practice guideline recognizes HBOT as an option for SSNHL treatment, particularly within 2 weeks of onset.

Key Finding: Cochrane review: HBOT significantly improves hearing in ISSHL, with a 22% greater chance of ≥25 dB improvement versus controls (NNT=5).

Key Finding: UHMS approved ISSHL as newest HBOT indication. ISSHL is characterised by hypoxia in the perilymph; HBOT restores oxygen to the organ of Corti.

Key Finding: Meta-analysis comparing salvage treatments for refractory SSNHL shows HBOT provides comparable hearing improvement to intratympanic steroid injection.

Key Finding: Comprehensive JAMA review of NSTIs: HBOT is recommended as adjunctive therapy alongside surgery and antibiotics for these severe life-threatening infections.

Key Finding: Study demonstrates that prompt HBOT as adjunctive therapy significantly reduces both mortality and amputation rates in necrotizing soft tissue infections.

Key Finding: Authoritative NEJM review of NSTIs covering pathogenesis, diagnosis, and treatment including HBOT as an adjunctive modality for these devastating infections.

Key Finding: Updated review discusses the latest evidence for NSTI treatment including HBOT, noting incidence varies from 0.86 to 32.64 per 100,000 person-years.

Key Finding: Reviews HBOT's direct antimicrobial mechanisms: bactericidal effects on anaerobes, enhanced leukocyte killing, and synergy with antibiotics in treating infections.

Key Finding: Reviews clinical guidelines for NSTI management; HBOT recommended as adjuvant therapy to reduce morbidity and mortality alongside surgical debridement.

Key Finding: Analysis of survival outcomes suggests HBOT improves survival when added to standard surgical and antibiotic treatment for NSTIs.

Key Finding: Evidence-based review: adjunctive HBOT is a rational addition to the treatment of NSTIs due to its antimicrobial and tissue-preserving effects.

Key Finding: Reviews treatment approaches for NSTIs: HBOT complements surgical debridement by inhibiting anaerobic bacteria and promoting healing at wound margins.

Key Finding: Classic review: necrotizing fasciitis requires aggressive multimodal treatment; HBOT provides bactericidal effects against anaerobic organisms driving the infection.

Key Finding: UHMS position paper: chronic refractory osteomyelitis is a CMS-approved indication for adjunctive HBOT when standard surgery and antibiotics fail.

Key Finding: Observational study shows HBOT significantly improves infection clearance rates in chronic refractory foot osteomyelitis where traditional approaches fall short.

Key Finding: UHMS comprehensive review: HBOT restores oxygen tension in infected bone, enhances neutrophil bactericidal activity, and potentiates antibiotic efficacy.

Key Finding: Case demonstrates resolution of chronic refractory osteomyelitis after adjunctive HBOT following multiple failed courses of antibiotics and surgeries.

Key Finding: Systematic review confirms HBOT is an effective adjunctive measure in treating chronic osteomyelitis, with favorable outcomes and manageable complications.

Key Finding: Landmark study: 40 patients with chronic osteomyelitis treated with adjunctive HBOT had only 15% recurrence rate at 2-year follow-up.

Key Finding: 28 consecutive patients with refractory osteomyelitis treated with HBOT showed significantly improved bone healing and infection clearance rates.

Key Finding: HBOT enhances bone and soft tissue healing in ischemic tissue, providing encouraging outcomes for chronic refractory osteomyelitis treatment.

Key Finding: HBOT provides significant benefit for hemodialysis patients with chronic osteomyelitis, a high-risk population where standard treatments often fail.

Key Finding: Reviews HBOT as Medicare-approved treatment for chronic non-healing wounds and radiation necrosis, with established protocols for osteomyelitis.

Key Finding: Comprehensive review: HBOT rescues compromised grafts and flaps by improving oxygenation, promoting angiogenesis, and reducing ischemia-reperfusion injury.

Key Finding: Clinical evaluation demonstrates HBOT can successfully salvage compromised local and regional skin flaps that would otherwise progress to failure.

Key Finding: HBOT reverses wound hypoxia and hypoperfusion in compromised grafts and flaps, offering additional physiologic benefits when standard wound therapy fails.

Key Finding: Reviews therapeutic mechanisms relevant to plastic and reconstructive surgery: HBOT improves tissue oxygenation and promotes healing of compromised tissue.

Key Finding: Systematic review of clinical evidence confirms HBOT efficacy for wound healing and limb salvage, including compromised surgical reconstructions.

Key Finding: Retrospective study: HBOT prevented skin necrosis and framework exposure after complex microtia reconstruction, improving surgical outcomes.

Key Finding: HBOT significantly benefits ischemic head and neck flaps by decreasing local tissue edema and improving oxygen delivery to compromised tissues.

Key Finding: Experimental study: HBOT significantly improved survival of skin flaps subjected to total venous occlusion compared to controls.

Key Finding: Demonstrates that compromised free flaps exist on a salvageability spectrum; HBOT can rescue partially ischemic flaps before complete loss occurs.

Key Finding: Confirms HBOT as a useful adjunctive treatment for complicated wounds including compromised skin grafts and flaps in paediatric patients.

Key Finding: UHMS review: consistently positive evidence shows HBOT prevents dermal ischemia, reduces edema, preserves the zone of stasis, and reduces mortality in burns.

Key Finding: Comprehensive review of 5 decades of evidence: identifies optimal HBOT dosage parameters linked to positive outcomes in thermal burns.

Key Finding: Review evaluates oxygen delivery methods for burns: HBOT shows superior effectiveness for thermal burn wound healing compared to standard care alone.

Key Finding: Cochrane review evaluates the evidence for HBOT in burns: supports further investigation of HBOT's role in reducing hospital stay and surgical interventions.

Key Finding: UHMS review: clinical reports consistently show HBOT reduces mortality, length of hospital stay, number of surgeries, and cost of care in thermal burns.

Key Finding: HBOT improves tissue hypoxia, neovascularization, and reduces pathologic inflammation in burns, with improved and faster wound healing outcomes.

Key Finding: Reviews 55+ years of experimental and clinical HBOT use in burns since 1965, documenting consistent improvements in healing and outcomes.

Key Finding: HBOT reduces tissue hypoxia, pathological inflammation, and augments neovascularization, supporting its integration as adjunctive burn care.

Key Finding: Human study demonstrates HBOT has antinociceptive effects and attenuates central sensitization (secondary hyperalgesia) after thermal injury.

Key Finding: Landmark review establishing HBOT as an important adjunct for thermal burns, decompression sickness, gas embolism, and CO poisoning.

Key Finding: UHMS current recommendations: recompression is definitive treatment for gas embolism. HBOT physically reduces bubble size and restores tissue oxygenation.

Key Finding: Authoritative NEJM review: HBOT is the treatment of choice for arterial gas embolism, providing rapid bubble compression and tissue oxygenation.

Key Finding: Lancet review: HBOT reduces bubble size by Boyle's law, restores blood flow, and corrects tissue hypoxia in both arterial gas embolism and decompression sickness.

Key Finding: UHMS guidelines: recompression with HBOT recommended for all symptomatic gas embolism cases; earlier treatment yields better neurological outcomes.

Key Finding: Reviews iatrogenic air embolism mechanisms and therapies: HBOT remains the primary treatment for significant vascular air embolism events.

Key Finding: New HBOT protocol demonstrates improved neurological outcomes in patients with arterial and venous gas embolism from hydrogen peroxide ingestion.

Key Finding: Prompt HBOT results in significantly improved outcomes in air embolism; most cases are iatrogenic, making rapid diagnosis and referral critical.

Key Finding: Comprehensive pathophysiology review: HBOT is the definitive treatment for both venous and arterial gas embolism based on physical and physiological principles.

Key Finding: Reviews HBOT as primary treatment for gas embolism from iatrogenic and diving causes, with mechanisms of bubble compression and nitrogen washout.

Key Finding: UHMS position: all patients with symptomatic gas embolism should receive HBOT; treatment should not be delayed for diagnostic imaging.

Key Finding: Cochrane review of RCTs: HBOT remains the primary treatment for moderate-to-severe CO poisoning, reducing COHb half-life from 5 hours to 20 minutes.

Key Finding: CO poisoning affects 50,000/year in the US with ~40% developing neurocognitive deficits. HBOT significantly reduces mortality and neurological sequelae.

Key Finding: Meta-analysis of RCTs: HBOT reduces delayed neurological sequelae in CO poisoning compared to normobaric oxygen therapy.

Key Finding: Canadian Medical Association Journal review: HBOT is recommended for severe CO poisoning, pregnancy, and any neurological symptoms.

Key Finding: NEJM review: HBOT reduces carboxyhemoglobin half-life to ~20 minutes (vs 5 hours on room air), preventing delayed neuropsychological syndrome.

Key Finding: CO poisoning in pregnancy carries 36-67% fetal mortality. HBOT treatment associated with favorable long-term fetal outcomes in this population.

Key Finding: Critical review of outcome studies supports HBOT over normobaric oxygen for preventing delayed neurological sequelae in CO poisoning.

Key Finding: CO poisoning causes tissue hypoxia through multiple mechanisms; HBOT rapidly displaces CO from hemoglobin and mitochondrial cytochrome oxidase.

Key Finding: Cochrane systematic review of 6 RCTs evaluating HBOT for CO poisoning, with evidence supporting its use in preventing neurological sequelae.

Key Finding: US Air Force experience: 300+ CO poisoning patients treated with HBOT including 14 infants under age 2, demonstrating safety and efficacy across age groups.

Key Finding: UHMS position paper: HBOT is critical adjunct for gas gangrene, creating an oxygen-rich environment toxic to anaerobic Clostridium and halting toxin production.

Key Finding: Comprehensive review: ~1000 cases/year in the US. HBOT is a key adjunctive therapy that inhibits clostridial toxin production and promotes tissue demarcation.

Key Finding: Landmark study of 139 patients: HBOT as adjunct to surgery achieved 81% overall survival in gas gangrene, demonstrating improved tissue preservation.

Key Finding: Duke University 10-year experience: 49 patients with clostridial myonecrosis treated with HBOT; 92.3% survival for extremity involvement.

Key Finding: 32 patients with gas gangrene treated 1971-1987: HBOT combined with surgery and antibiotics improved survival and limb preservation.

Key Finding: US Air Force experience: 77 gas gangrene patients treated with HBOT since 1965, demonstrating extensive military application and clinical benefit.

Key Finding: UHMS comprehensive review of evidence supporting HBOT as essential adjunct for gas gangrene, complementing surgical debridement and antibiotics.

Key Finding: Establishes the scientific rationale for HBOT in gas gangrene: direct toxicity to Clostridium, enhanced leukocyte killing, and improved tissue oxygenation.

Key Finding: 32 gas gangrene patients: HBOT allowed more conservative surgery by clearly demarcating viable from non-viable tissue, reducing amputation rates.

Key Finding: Rare case of orbital gas gangrene successfully treated with HBOT as adjunct, demonstrating benefit even in uncommon anatomic presentations.

Key Finding: UHMS review: HBOT is beneficial for crush injuries, compartment syndromes, burns, frostbite, and threatened flaps — all acute traumatic ischemias.

Key Finding: HBOT addresses the two unifying components of traumatic ischemias: trauma and ischemia, by delivering oxygen beyond the zone of obvious injury.

Key Finding: UHMS review: crush injuries range from minor contusions to limb-threatening damage; HBOT reduces edema and preserves marginally viable tissue.

Key Finding: Proposes objective criteria for using HBOT in crush injuries and compartment syndromes, establishing clinical decision-making framework.

Key Finding: Evidence-based review: animal models consistently show HBOT improves outcomes in crush injury and compartment syndrome with better tissue preservation.

Key Finding: HBOT enhances tissue oxygen content in extremity trauma, complementing fracture fixation and macrovascular repair in crush-injured limbs.

Key Finding: Case report demonstrates successful adjunctive HBOT treatment for hand crush injury following motor vehicle accident, preserving limb function.

Key Finding: Reviews physiological rationale: HBOT reduces ischemia-reperfusion injury, decreases edema, and rescues cells in the ischemic penumbra zone.

Key Finding: Reviews clinical and experimental data supporting HBOT as adjunct to reconstructive surgery for crush injuries and traumatic ischemia.

Key Finding: Reviews crush syndrome management: early diagnosis and aggressive treatment including HBOT are vital to prevent multiorgan failure and limb loss.

Key Finding: UHMS current recommendations: recompression with HBOT is the definitive treatment for DCS. Earlier treatment yields significantly better outcomes.

Key Finding: RCT demonstrates that shorter recompression schedules may be as effective as USN Treatment Table 6 for mild DCS presentations.

Key Finding: 546 DCI patients: delayed HBOT still provides benefit, but treatment delay worsens outcomes. Earlier recompression significantly improves recovery.

Key Finding: Review of 140 DCS cases: short, no-air-break HBOT tables provided effective treatment even when recompression was delayed beyond 24 hours.

Key Finding: Inner ear DCS is increasingly recognised in recreational diving; HBOT recompression provides effective treatment, especially with patent foramen ovale.

Key Finding: Lancet review: recompression is the definitive treatment for all forms of decompression illness, with HBOT physically crushing nitrogen bubbles.

Key Finding: USN TT9 provides a standardized HBOT protocol for incomplete resolution of DCS after initial treatment, establishing dosing guidelines.

Key Finding: Helium-oxygen recompression treatment shows improved outcomes in neurologic DCS compared to traditional air-oxygen tables.

Key Finding: Reviews in-water recompression as emergency treatment in remote locations; reinforces that chamber-based HBOT remains the gold standard for DCS.

Key Finding: HBOT is essential for spinal cord DCS from diving; early recompression prevents permanent paralysis by resolving nitrogen bubbles in spinal vasculature.

Key Finding: Landmark JAMA paper establishing HBOT as bridge therapy for exceptional blood loss anemia, dissolving oxygen directly in plasma to sustain life.

Key Finding: JAMA case demonstrating survival from severe anemia without blood transfusion using HBOT to maintain tissue oxygenation during marrow recovery.

Key Finding: HBOT used successfully for severe pernicious anemia in a patient unable to receive transfusion, extending its application beyond acute blood loss.

Key Finding: Patient with hemoglobin of 1.9 g/dL survived using HBOT as bridge therapy. Demonstrates HBOT can sustain life at otherwise incompatible hemoglobin levels.

Key Finding: HBOT remains a critical oxygen therapeutic when transfusion is refused (religious beliefs), unavailable (no cross-match), or in remote locations.

Key Finding: Reviews HBOT as part of emergency management for life-threatening anemia when blood products cannot be administered.

Key Finding: HBOT provides tissue oxygenation in sickle cell crisis, demonstrating utility for end-organ damage from severe anemia and vaso-occlusion.

Key Finding: Reviews bloodless medicine strategies: HBOT is a cornerstone therapy for patients who cannot receive transfusion, dissolving oxygen in plasma.

Key Finding: Reviews management of critical anemia: HBOT provides supplemental tissue oxygenation when hemoglobin levels are insufficient for oxygen transport.

Key Finding: Early demonstration of HBOT enabling cancer treatment in severely anemic patients who could not receive blood transfusion.

Key Finding: HBOT as adjuvant treatment for brain abscesses leads to faster recovery and improved outcomes despite the condition's substantial case fatality rates.

Key Finding: Population-based cohort: HBOT-treated brain abscess patients had 80% good outcome vs 45% in controls, demonstrating significant clinical benefit.

Key Finding: UHMS comprehensive review: HBOT enhances antibiotic efficacy in hypoxic abscess tissue, reduces edema, and inhibits anaerobic organisms.

Key Finding: Updated UHMS manual: HBOT is recommended adjunct for cerebral abscess, subdural empyema, and epidural empyema alongside surgery and antibiotics.

Key Finding: HBOT combined with stereotactic aspiration reduced antibiotic treatment duration and achieved 0% recurrence rate in 13 brain abscess patients.

Key Finding: 5 children with brain abscesses treated with multimodal approach including HBOT showed favorable outcomes, supporting pediatric HBOT use.

Key Finding: UHMS review of evidence supporting HBOT as adjunct for intracranial abscess, with rationale based on enhanced oxygen delivery to peri-abscess tissue.

Key Finding: Experimental study: HBOT is most effective in the early cerebritis stage of brain abscess, supporting early initiation of treatment.

Key Finding: Reviews advances in brain abscess management including HBOT as a promising adjunctive modality to improve treatment outcomes.

Key Finding: HBOT combined with antimicrobials successfully treated rare listerial brain abscess in an immunocompromised patient where standard therapy was insufficient.